



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>07039-427001</b>	Application No. <b>10/619,824</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Chen et al.</b>	
		Filing Date <b>July 14, 2003</b>	Group Art Unit <b>1644</b>

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	WO 03/49755	06/19/03	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AC	Foell et al., "CD137-Mediated T Cell Co-Stimulation Terminates Existing Autoimmune Disease in SLE-Prone NZB/NZW F1 Mice," <u>Ann. N.Y. Acad. Sci.</u> , 2003, 987:230-235
	AD	Sun et al., "Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis," <u>J. Immunol.</u> , 2002, 168:1457-1465
	AE	Sun et al., "Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease," <u>Nature Medicine</u> , 2002, 8(12):1405-1413
	AF	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	